Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.
Saved in:
| Title: | Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. |
|---|---|
| Authors: | Savoca A; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Zindel D; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Polanski R; AstraZeneca Pharma Poland Sp. z o.o., R&D, Warsaw Clinical Operational Hub, Warsaw, Poland., Kostomiris DH; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca (United States), Waltham, Massachusetts., Pirmoradian M; Biomarker, Discovery and Development, Translational Science and Experimental Medicine, R&D, AstraZeneca, Gothenburg, Sweden., Swaih AM; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Talbot S; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Floc'h N; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Winlow P; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Davey PRJ; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Longmire D; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Wadforth E; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Lewis HJ; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Smith A; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Lipka R; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Wilson J; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Britton DJ; Kinomica Ltd, Macclesfield, United Kingdom., Dokal AD; Kinomica Ltd, Macclesfield, United Kingdom., Smith R; Kinomica Ltd, Macclesfield, United Kingdom., Thomson C; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., McCoull W; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2026 Jul 02; Vol. 25 (7), pp. 1157-1167. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41622600 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Savoca+A%22">Savoca A</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Zindel+D%22">Zindel D</searchLink>; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Polanski+R%22">Polanski R</searchLink>; AstraZeneca Pharma Poland Sp. z o.o., R&D, Warsaw Clinical Operational Hub, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Kostomiris+DH%22">Kostomiris DH</searchLink>; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca (United States), Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Pirmoradian+M%22">Pirmoradian M</searchLink>; Biomarker, Discovery and Development, Translational Science and Experimental Medicine, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Swaih+AM%22">Swaih AM</searchLink>; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Talbot+S%22">Talbot S</searchLink>; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Floc'h+N%22">Floc'h N</searchLink>; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Winlow+P%22">Winlow P</searchLink>; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Davey+PRJ%22">Davey PRJ</searchLink>; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Longmire+D%22">Longmire D</searchLink>; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wadforth+E%22">Wadforth E</searchLink>; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lewis+HJ%22">Lewis HJ</searchLink>; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Smith+A%22">Smith A</searchLink>; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lipka+R%22">Lipka R</searchLink>; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wilson+J%22">Wilson J</searchLink>; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Britton+DJ%22">Britton DJ</searchLink>; Kinomica Ltd, Macclesfield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Dokal+AD%22">Dokal AD</searchLink>; Kinomica Ltd, Macclesfield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Smith+R%22">Smith R</searchLink>; Kinomica Ltd, Macclesfield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Thomson+C%22">Thomson C</searchLink>; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McCoull+W%22">McCoull W</searchLink>; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2026 Jul 02; Vol. 25 (7), pp. 1157-1167. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41622600 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/1535-7163.MCT-25-0082 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1157 Titles: – TitleFull: Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Savoca A – PersonEntity: Name: NameFull: Zindel D – PersonEntity: Name: NameFull: Polanski R – PersonEntity: Name: NameFull: Kostomiris DH – PersonEntity: Name: NameFull: Pirmoradian M – PersonEntity: Name: NameFull: Swaih AM – PersonEntity: Name: NameFull: Talbot S – PersonEntity: Name: NameFull: Floc'h N – PersonEntity: Name: NameFull: Winlow P – PersonEntity: Name: NameFull: Davey PRJ – PersonEntity: Name: NameFull: Longmire D – PersonEntity: Name: NameFull: Wadforth E – PersonEntity: Name: NameFull: Lewis HJ – PersonEntity: Name: NameFull: Smith A – PersonEntity: Name: NameFull: Lipka R – PersonEntity: Name: NameFull: Wilson J – PersonEntity: Name: NameFull: Britton DJ – PersonEntity: Name: NameFull: Dokal AD – PersonEntity: Name: NameFull: Smith R – PersonEntity: Name: NameFull: Thomson C – PersonEntity: Name: NameFull: McCoull W IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 07 Text: 2026 Jul 02 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1538-8514 Numbering: – Type: volume Value: 25 – Type: issue Value: 7 Titles: – TitleFull: Molecular cancer therapeutics Type: main |
| ResultId | 1 |
